Specifically, cAMP signaling has been reported to exert anti-lymphoma effects and, to the best of our knowledge, GNAS mutations are not recurrent in DLBCL and follicular lymphoma [24, 25]. This evidence concerns the gene GNAS and follicular lymphoma.